Does dexmedetomidine prevent colistin nephrotoxicity?

Gamze Talih; Aliye Esmaoğ; lu; Adnan Bayram; Cevat Yazici; Kemal Deniz; Tutkun Talih

doi:10.1016/j.bjane.2018.01.021

Scientific Article

Does dexmedetomidine prevent colistin nephrotoxicity?

Dexmedetomidina impede a nefrotoxicidade da colistina?

Gamze Talih; Aliye Esmaoğ; lu; Adnan Bayram; Cevat Yazici; Kemal Deniz; Tutkun Talih

http://dx.doi.org/10.1016/j.bjane.2018.01.021 Braz J Anesthesiol, vol.68, n4, p.383-387, 2018

PDF

Downloads: 0

Abstract

Abstract Background In this study, we aimed to investigate the effect of dexmedetomidine on colistin nephrotoxicity in rats. Methods Thirty-two Wistar albino rats were allocated into four groups. Intraperitoneal (ip) saline at 1 mL.kg-1 was administered to the control group and 10 mg.kg-1 ip colistin was given to the colistin group. In the DEX10 group 10 mcg.kg-1 dexmedetomidine ip was given 20 min before the injection of 10 mg.kg-1 ip colistin. In the DEX20 group ip 20 mcg.kg-1 dexmedetomidine was injected 20 min before the administration of 10 mg.kg-1 ip colistin. These treatments were continued twice a day for seven days. Samples were taken on the eighth day. BUN, Cr, KIM-1, TAS, and TOS were examined in blood samples and caspase-3 was examined in kidney tissue samples. Results The values for BUN, Cr and TOS were significantly higher in the colistin group than in the control group. BUN, Cr and TOS changes in the DEX10 and DEX20 groups were not significant compared with the control group but they were significantly lower compared with the colistin group. TAS values in the DEX10 group were significantly lower than in the control group. Apoptotic activity was significantly higher in the colistin group compared with the control group, but there was no significant difference in terms of caspase-3 staining activity when DEX10 and DEX20 groups were compared with the control group. Conclusion Oxidative damage and apoptosis played roles in colistin nephrotoxicity, and colistin nephrotoxicity could be prevented by treatment with dexmedetomidine.

Keywords

Alpha-2 agonist, Colistin, Colistin nephrotoxicity, Dexmedetomidine

Resumo

Resumo Justificativa Neste estudo, buscamos investigar o efeito da dexmedetomidina sobre a nefrotoxicidade da colistina em ratos. Métodos Trinta e dois ratos Wistar albinos foram alocados em quatro grupos: o grupo controle recebeu 1 mL.kg-1 de solução salina intraperitoneal (ip); o grupo colistina recebeu 10 mg.kg-1 de colistina ip; o grupo DEX10 recebeu 10 mcg.kg-1 de dexmedetomidina ip 20 minutos antes da injeção de 10 mg.kg-1 de colistina ip; o grupo DEX20 recebeu 20 mcg.kg-1 de dexmedetomidina ip 20 minutos antes da administração de 10 mg.kg-1 de colistina ip. Estes tratamentos foram continuados duas vezes ao dia durante sete dias. As amostras foram colhidas no oitavo dia. BUN, Cr, KIM-1, TAS e TOS foram examinados nas amostras de sangue e caspase-3 foi examinada nas amostras de tecido renal. Resultados Os valores de BUN, Cr e TOS foram significativamente maiores no grupo colistina do que no grupo controle. As alterações em BUN, Cr e TOS nos grupos DEX10 e DEX20 não foram significativas em comparação com o grupo controle, mas foram significativamente menores em comparação com o grupo colistina. Os valores de TAS no grupo DEX10 foram significativamente menores do que no grupo controle. A atividade apoptótica foi significativamente maior no grupo colistina em comparação com o grupo controle, mas não houve diferença significativa em termos de atividade na coloração da caspase-3 quando os grupos DEX10 e DEX20 foram comparados com o grupo controle. Conclusão O dano oxidativo e a apoptose desempenharam papéis na nefrotoxicidade da colistina e a nefrotoxicidade de colistina pode ser prevenida pelo tratamento com dexmedetomidina.

Palavras-chave

Alpha-2 agonista, Colistina, Nefrotoxicidade da colistina, Dexmedetomidina

References

Torres A, Ferrer M, Badia JR. Treatment guidelines and outcomes of hospital-acquired and ventilator-associated pneumonia. Clin Infect Dis. 2010;51:1114.

Alp E, Güven M, Yildiz O, Aygen B, Voss A, Doganay M. Incidence, risk factors and mortality of nosocomial pneumonia in intensive care units: a prospective study. Ann Clin Microbiol Antimicrob. 2004;3:17.

Mehndiratta MM, Nayak R, Ali S. Ventilators in ICU: a boon or burden. Ann Indian Acad Neurol. 2016;19:69-73.

Yilmaz GR, Guven T, Guner R. Colistin alone or combined with sulbactam or carbapenem against A. baumannii in ventilator-associated pneumonia. J Infect Dev Ctries. 2015;9:476-85.

Suzuki T, Yamaguchi H, Ogura J. Megalin contributes to kidney accumulation and nephrotoxicity of colistin. Antimicrob Agents Chemother. 2013;57:6319-24.

Ozkan G, Ulusoy S, Orem A. How does colistin-induced nephropathy develop and can it be treated?. Antimicrob Agents Chemother. 2013;57:3463-9.

Ghlissi Z, Hakim A, Sila A. Evaluation of efficacy of natural astaxanthin and vitamin E in prevention of colistin-induced nephrotoxicity in the rat model. Environ Toxicol Phar. 2014;37:960-6.

Yousef JM, Chen G, Hill PA. Melatonin attenuates colistin-induced nephrotoxicity in rats. Antimicrob Agents Chemother. 2011;55:4044-9.

Yousef JM, Chen G, Hill PA. Ascorbic acid protects against the nephrotoxicity and apoptosis caused by colistin and affects its pharmacokinetics. J Antimicrob Chemother. 2012;67:452-9.

Gertler R, Brown HC, Mitchell DH, Silvius EN. Dexmedetomidine: a novel sedative-analgesic agent. Proc (Bayl Univ Med Cent). 2001;14:13-21.

Khan ZP, Ferguson CN, Jones RM. Alpha-2 and imidazoline receptor agonists. Their pharmacology and therapeutic role. Anaesthesia. 1999;54:146-65.

Ozyilmaz E, Ebinc FA, Derici U. Could nephrotoxicity due to colistin be ameliorated with the use of N-acetylcysteine?. Intensive Care Med. 2011;37:41-146.

Keirstead ND, Wagoner MP, Bentley P. Early prediction of polymyxin-induced nephrotoxicity with next-generation urinary kidney injury biomarkers. Toxicol Sci. 2014;137:278-91.

Pettinger WA. Renal alpha 2-adrenergic receptors and hypertension. Hypertension. 1987;9:3-6.

Bayram A, Esmaoglu A, Akin A. The effects of intraoperative infusion of dexmedetomidine on early renal function after percutaneous nephrolithotomy. Acta Anaesthesiol Scand. 2011;55:539-44.

Bayram A, Ulgey A, Baykan A. The effects of dexmedetomidine on early stage renal functions in pediatric patients undergoing cardiac angiography using non-ionic contrast media: a double-blind, randomized clinical trial. Paediatr Anaesth. 2014;24:426-32.

Bhana N, Goa KL, McClellan KJ. Dexmedetomidine. Drugs. 2000;59:263-8.

Billings FT, Chen SW, Kim M. alpha2-Adrenergic agonists protect against radiocontrast-induced nephropathy in mice. Am J Physiol Renal Physiol. 2008;295.

Si YN, Bao HG, Xu L. Dexmedetomidine protects against ischemia/reperfusion injury in rat kidney. Eur Rev Med Pharmacol Sci. 2014;18:1843-51.

Yang B, El Nahas AM, Thomas GL. Caspase-3 and apoptosis in experimental chronic renal scarring. Kidney Int. 2001;60:1765-76.

Does dexmedetomidine prevent colistin nephrotoxicity?

Dexmedetomidina impede a nefrotoxicidade da colistina?

Gamze Talih; Aliye Esmaoğ; lu; Adnan Bayram; Cevat Yazici; Kemal Deniz; Tutkun Talih

Abstract

Keywords

Resumo

Palavras-chave

References

Links

Share

Braz J Anesthesiol